BevirimatCAS# 174022-42-5 |
- Amyloid β-Peptide (10-20) (human)
Catalog No.:BCC1026
CAS No.:152286-31-2
- Amyloid β-Protein (1-15)
Catalog No.:BCC1003
CAS No.:183745-81-5
- Beta-Amyloid (1-11)
Catalog No.:BCC1002
CAS No.:190436-05-6
- Myelin Basic Protein (68-82), guinea pig
Catalog No.:BCC1020
CAS No.:98474-59-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 174022-42-5 | SDF | Download SDF |
| PubChem ID | 457928 | Appearance | Powder |
| Formula | C36H56O6 | M.Wt | 584.83 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Synonyms | PA-457; MPC-4326; FH11327; YK FH312 | ||
| Solubility | DMSO : ≥ 50 mg/mL (85.49 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-(3-carboxy-3-methylbutanoyl)oxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid | ||
| SMILES | CC(=C)C1CCC2(C1C3CCC4C5(CCC(C(C5CCC4(C3(CC2)C)C)(C)C)OC(=O)CC(C)(C)C(=O)O)C)C(=O)O | ||
| Standard InChIKey | YJEJKUQEXFSVCJ-WRFMNRASSA-N | ||
| Standard InChI | InChI=1S/C36H56O6/c1-21(2)22-12-17-36(30(40)41)19-18-34(8)23(28(22)36)10-11-25-33(7)15-14-26(42-27(37)20-31(3,4)29(38)39)32(5,6)24(33)13-16-35(25,34)9/h22-26,28H,1,10-20H2,2-9H3,(H,38,39)(H,40,41)/t22-,23+,24-,25+,26-,28+,33-,34+,35+,36-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Bevirimat is a HIV-1 maturation inhibitor. |
| Targets | HIV |
Bevirimat Dilution Calculator
Bevirimat Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.7099 mL | 8.5495 mL | 17.099 mL | 34.198 mL | 42.7475 mL |
| 5 mM | 0.342 mL | 1.7099 mL | 3.4198 mL | 6.8396 mL | 8.5495 mL |
| 10 mM | 0.171 mL | 0.8549 mL | 1.7099 mL | 3.4198 mL | 4.2747 mL |
| 50 mM | 0.0342 mL | 0.171 mL | 0.342 mL | 0.684 mL | 0.8549 mL |
| 100 mM | 0.0171 mL | 0.0855 mL | 0.171 mL | 0.342 mL | 0.4275 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Bevirimat(YK FH312; FH11327; MPC-4326) is an anti-HIV drug derived from a betulinic acid-like compound; is believed to inhibit HIV by a novel mechanism, so-called maturation inhibition. IC50 value: Target: Anti-HIV Like protease inhibitors, bevirimat and other maturation inhibitors interfere with protease processing of newly translated HIV polyprotein precursor, called gag. Bevirimat prevents this viral replication by specifically inhibiting cleavage of the capsid protein (CA) from the SP1 spacer protein.
References:
[1]. Smith PF, et al. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother. 2007 Oct;51(10):3574-81.
[2]. Salzwedel K, et al. Maturation inhibitors: a new therapeutic class targets the virus structure. AIDS Rev. 2007 Jul-Sep;9(3):162-72.
[3]. Martin DE, et al. Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother. 2008;19(3):107-13.
- Dehydroabietic acid
Catalog No.:BCN1119
CAS No.:1740-19-8
- Nepicastat
Catalog No.:BCC1795
CAS No.:173997-05-2
- 5-Acetyl-6-hydroxy-2-(1-hydroxy-1-methylethyl)benzofuran
Catalog No.:BCN7495
CAS No.:173992-05-7
- 22-Hydroxy-3-oxo-12-ursen-30-oic acid
Catalog No.:BCN1526
CAS No.:173991-81-6
- Tanshinone IIB
Catalog No.:BCN1118
CAS No.:17397-93-2
- SYM 2206
Catalog No.:BCC6866
CAS No.:173952-44-8
- Isogambogenin
Catalog No.:BCN3066
CAS No.:173938-23-3
- Atrasentan
Catalog No.:BCC1379
CAS No.:173937-91-2
- Gambogenic acid
Catalog No.:BCN3077
CAS No.:173932-75-7
- Corynoxine B
Catalog No.:BCN8454
CAS No.:17391-18-3
- Isocarapanaubine
Catalog No.:BCN1117
CAS No.:17391-09-2
- FR 171113
Catalog No.:BCC7734
CAS No.:173904-50-2
- Tomatine
Catalog No.:BCN2966
CAS No.:17406-45-0
- 3-(4-Pyridyl)-D-Alanine.2HCl
Catalog No.:BCC2650
CAS No.:174096-41-4
- Aristolochic acid D
Catalog No.:BCN2902
CAS No.:17413-38-6
- 3-Chloro-4-hydroxypiperidin-2-one
Catalog No.:BCN3992
CAS No.:174204-83-2
- Methyl 3-(2,4-dihydroxyphenyl)propionate
Catalog No.:BCN1525
CAS No.:17422-90-1
- Pancixanthone A
Catalog No.:BCN7379
CAS No.:174232-30-5
- Apigenin 7-O-(2G-rhamnosyl)gentiobioside
Catalog No.:BCN1524
CAS No.:174284-20-9
- Epimedin K
Catalog No.:BCN8201
CAS No.:174286-13-6
- Caohuoside E
Catalog No.:BCN8198
CAS No.:174286-23-8
- Astragaloside
Catalog No.:BCN5959
CAS No.:17429-69-5
- Picropodophyllotoxin
Catalog No.:BCN2585
CAS No.:17434-18-3
- Tsugaric acid A
Catalog No.:BCN2980
CAS No.:174391-64-1
Incorporation of Privileged Structures into Bevirimat Can Improve Activity against Wild-Type and Bevirimat-Resistant HIV-1.[Pubmed:27676157]
J Med Chem. 2016 Oct 13;59(19):9262-9268.
Two "privileged fragments", caffeic acid and piperazine, were integrated into Bevirimat producing new derivatives with improved activity against HIV-1/NL4-3 and NL4-3/V370A carrying the most prevalent Bevirimat-resistant polymorphism. The activity of one of these, 18c, was increased by 3-fold against NL4-3 and 51-fold against NL4-3/V370A. Moreover, 18c is a maturation inhibitor with improved metabolic stability. Our study suggested that integration of privileged motifs into promising natural product skeletons is an effective strategy for discovering potent derivatives.
Synthesis and biological evaluation of a new derivative of bevirimat that targets the Gag CA-SP1 cleavage site.[Pubmed:23399723]
Eur J Med Chem. 2013 Apr;62:453-65.
Bevirimat (2), the first-in-class HIV-1 maturation inhibitor, shows a low efficacy due essentially to the natural polymorphism of its target, the CA-SP1 junction. Moreover, its low hydrosolubility makes it difficult to study its interaction with the CA-SP1 junction. We have synthesized new derivatives of Bevirimat by adding different hydrophilic substituents at the C-28 position to improve their hydrosolubility and perform the structural study of a complex by NMR. Synthesis of the new derivatives, the effect of substituents at the C-28 position and their hydrosolubility are discussed. The ability of these molecules to inhibit viral infection and their cytotoxicity is assessed. Compared to the well-known Bevirimat (2), one of our compounds (16) shows a higher hydrosolubility associated with a 2.5 fold increase in activity, a higher selectivity index and a better antiviral profile. Moreover, for the first time a direct interaction between a derivative of Bevirimat (16) and the domain CA-SP1-NC is shown by NMR. Information from this study should allow us to decipher the mechanism by which Bevirimat inhibits HIV-1 maturation and how the natural polymorphism of the spacer peptide SP1 triggers resistance to inhibitors.
Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors.[Pubmed:26482309]
Antimicrob Agents Chemother. 2015 Oct 19;60(1):190-7.
Concomitant with the release of human immunodeficiency virus type 1 (HIV-1) particles from the infected cell, the viral protease cleaves the Gag polyprotein precursor at a number of sites to trigger virus maturation. We previously reported that a betulinic acid-derived compound, Bevirimat (BVM), blocks HIV-1 maturation by disrupting a late step in protease-mediated Gag processing: the cleavage of the capsid-spacer peptide 1 (CA-SP1) intermediate to mature CA. BVM was shown in multiple clinical trials to be safe and effective in reducing viral loads in HIV-1-infected patients. However, naturally occurring polymorphisms in the SP1 region of Gag (e.g., SP1-V7A) led to a variable response in some BVM-treated patients. The reduced susceptibility of SP1-polymorphic HIV-1 to BVM resulted in the discontinuation of its clinical development. To overcome the loss of BVM activity induced by polymorphisms in SP1, we carried out an extensive medicinal chemistry campaign to develop novel maturation inhibitors. In this study, we focused on alkyl amine derivatives modified at the C-28 position of the BVM scaffold. We identified a set of derivatives that are markedly more potent than BVM against an HIV-1 clade B clone (NL4-3) and show robust antiviral activity against a variant of NL4-3 containing the V7A polymorphism in SP1. One of the most potent of these compounds also strongly inhibited a multiclade panel of primary HIV-1 isolates. These data demonstrate that C-28 alkyl amine derivatives of BVM can, to a large extent, overcome the loss of susceptibility imposed by polymorphisms in SP1.
New betulinic acid derivatives for bevirimat-resistant human immunodeficiency virus type-1.[Pubmed:23379607]
J Med Chem. 2013 Mar 14;56(5):2029-37.
Bevirimat (1, BVM) is an anti-HIV agent that blocks HIV-1 replication by interfering with HIV-1 Gag-SP1 processing at a late stage of viral maturation. However, clinical trials of 1 have revealed a high baseline drug resistance that is attributed to naturally occurring polymorphisms in HIV-1 Gag. To overcome the drug resistance, 28 new derivatives of 1 were synthesized and tested against compound 1-resistant (BVM-R) HIV-1 variants. Among them, compound 6 exhibited much improved activity against several HIV-1 strains carrying BVM-R polymorphisms. Compound 6 was at least 20-fold more potent than 1 against the replication of NL4-3/V370A, which carries the most prevalent clinical BVM-R polymorphism in HIV-1 Gag-SP1. Thus, compound 6 merits further development as a potential anti-AIDS clinical trial candidate.
